Background to the NACB Tumor-Marker Guidelines
Here we report the updating and extension of practice guidelines first proposed in 2002 (3 ) . Undertaken under the direction of a steering committee appointed by the NACB (Table 1) , this process involved consideration of 16 specific cancer sites, together with quality requirements for well-established tumor markers and tumor markers being developed by use of new technologies (Table 2) . With its wide scope, this project is one of the most comprehensive and complex of its type to date. The draft guidelines were posted on the NACB website in July 2005 and were presented as an EduTrak at the 2005 Joint AACC/IFCC Annual meeting in Orlando, Florida. Informed comment was also actively sought from individuals, organizations, and other interested parties.
NACB Tumor-Marker Guideline Development Group
Nineteen subcommittees developed draft guidelines (Table 2) . Subcommittee members included individuals with extensive expertise in the science, technology, and clinical practice of tumor markers in academia, hospitals, and/or industry. In guidelines in which expert opinion is incorporated as part of the recommendations, bias, including conflict of interest, may intrude (4 ). Members of the in vitro diagnostic industry were deliberately included in the subcommittee membership to obtain a representative cross-section of experts and perspectives in the field. The disciplines of all authors are provided in a Supplemental Table attached to each paper (see Supplemental  Table 1 in the Data Supplement that accompanies the online version of this preamble at http://www. clinchem.org/content/vol54/issue11), together with statements of conflicts of interest, declared according to NACB requirements. This major undertaking has involved significant input from approximately 100 scientists and clinicians from more than 10 countries and with diverse backgrounds.
Methodological Approach
Extensive literature is available on the preparation (5, 6 ) and evaluation (7 ) of practice guidelines. Many experts have emphasized the importance of a good evidence base in developing such guidelines (5, 8 ) and the challenges of their effective implementation (9 -11 ) . Good methodology during guideline development is highly desirable, although it has recently been noted that good reporting of methodological quality does not necessarily lead to more valid recommendations or vice versa (12 ) .
A recent assessment of 9 clinical oncology practice guidelines has demonstrated significant heterogeneity in the development, structure, potential users, and endpoints of these guidelines, which the authors of the assessment concluded was not detrimental but rather was necessary to meet divergent demands (13 ) . No available guidelines are likely to be perfect in all situations-all have limitations, some of which the NACB Guidelines presented here undoubtedly share. Characteristics identified as critical to the effectiveness of practice guidelines, however, are a clear definition of purpose and intended audience (i.e., for the NACB Tumor-Marker Guidelines, to encourage more appropriate use of tumor markers by health professionals), adherence to methodological standards, and systematic evaluation (audit) of the clinical impact of the guidelines following their introduction (13 ) .
A relatively informal methodological approach was adopted, and subcommittee chairs were allowed considerable latitude. Consequently some reports are longer and more detailed than others. Although some of the diversity evident in the guidelines presented here undoubtedly reflects the predilection and idiosyncrasy of individual subcommittees, much of it arises from the different numbers of tumor markers described for each specific cancer as well as the variable maturity of clinical validation and currently available evidence for these markers. It is therefore not realistic to expect to achieve consistency of approach across the spectrum of cancers examined.
The subcommittees were, however, asked to follow a recommended structure (online Supplemental Table 2 ) when developing and formulating the guidelines and to consider each of the major potential clinical applications of tumor markers (screening/early detection, diagnosis, prognosis, treatment monitoring, and surveillance) to achieve a reasonably homogeneous presentation across cancer types. Subcommittees were also strongly encouraged to undertake as thorough a review of the literature as feasible, with particular attention given to reviews (including systematic reviews), prospective randomized trials that included the use of markers, and existing guidelines.
An important feature of the process was that each subcommittee was asked to compare its guidelines with those of other groups and to present these comparisons in tabular form, elaborating on any differences and also providing estimates of both the level of evidence (9 ) and the strength or grade of recommendation (14 ) ( Table 3 ) ascribable to each NACB recommendation. The level of evidence and strength or grade of recommendation, respectively, reflect the strength of published evidence supporting the recommendations made and the degree of consensus within the guideline development group, and the tables relating to individual malignancies provide a convenient summary of the relevant NACB Guidelines. When consensus could not be achieved within a subcommittee, an explanation is provided along with descriptions of and reasons for the conflicting views.
The final result is a set of practice guidelines that follow a reasonably homogeneous style and approach. The strength and type of evidence underlying each recommendation is clearly stated, together with an estimate of the confidence with which each recommendation has been made, so the reader can readily discern which recommendations are based on incontrovertible clinical evidence and which are based on the expert consensus of committee members.
Review and Refinement of the NACB Tumor-Marker Guidelines
Subcommittee chairs reviewed and responded to suggestions and corrections received following posting of the guidelines on the NACB website and other publicity. Comments received, and action taken in response to them, are presented in a supplement accompanying the relevant paper (see the online Data Supplement).
These NACB Guidelines will inevitably require updating, refinement, and modification in the future, as knowledge and understanding of tumor markers and their biological roles increases. As suggested in the very helpful AGREE (Appraisal of Guidelines Research and Evaluation) document (7 ), and reflecting work in progress for a number of tumor markers, when the guidelines are next updated it may be possible to include some estimate of the cost-effectiveness of tumor marker use, to take account of patients' views (psychological aspects of tumor marker use having only been touched on in the present guidelines), and to report on audit studies of their effectiveness. For this purpose it would be desirable to use a consultation form similar to that developed by the Scottish Intercollegiate Guideline Network [see, e.g., (15 ) ]. 
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IMPLEMENTATION OF THE NACB TUMOR-MARKER GUIDELINES
Adoption of these guidelines is voluntary; some recommendations may not be appropriate in all settings (e.g., clinical trials), and for effective implementation guidelines may require translation and/or other modification in some settings. There is good evidence that "lo- cally owned" guidelines are much more likely to be successfully adopted in routine clinical practice (6 ) . Additionally, carefully designed audit studies would be highly desirable before and after introduction of the guidelines (13 ) . These recommendations, which, to facilitate their dissemination, are being published in electronic form in a widely read journal, should encourage more optimal use of tumor-marker tests by clinical and laboratory staff, thereby better informing medical decisions directed toward improved clinical outcome and/or quality of life for increasing numbers of cancer patients. 
Assessment Criteria
Level of evidence (9 ) I Evidence from a single, high-powered, prospective, controlled study that is specifically designed to test marker, or evidence from a metaanalysis, pooled analysis, or overview of level II or III studies.
II
Evidence from a study in which marker data are determined in relationship to a prospective therapeutic trial that is performed to test therapeutic hypothesis but not specifically designed to test marker utility.
III
Evidence from large prospective studies.
IV
Evidence from small retrospective studies. V Evidence from small pilot studies.
Expert opinion Formal consensus of subcommittee members.
Strength of recommendation (14 ) High (A) Further research is very unlikely to change the panel's confidence in the estimate of effect.
Moderate (B)
Further research is likely to have an important impact on the panel's confidence in the estimate of effect and is likely to change the estimate.
Low (C)
Further research is very likely to have an important effect on the panel's confidence in the estimate of effect and is likely to change the estimate.
Very low (D)
Any estimate of effect is very uncertain.
